Dr Shabeed Chelakkadan

Paediatric Neurologist and Epileptologist with extensive experience in managing complex epilepsy syndromes, particularly drug-resistant epilepsy in children.

RESEARCH & CLINICAL TRAILS

 Current Research:

·  Do sharp waves in neonatal EEG predict clinical and developmental outcomes

·  Exploring the combined use of non-pharmacological therapies for children with drug-resistant epilepsy (Ketogenic Diet Therapy and Vagal Nerve Stimulation) through a scoping review and retrospective cohort study.

 Clinical Trials (Sub-Investigator):

·  A Phase 3, randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, and tolerability of Valbenazine for treating dyskinesia in cerebral palsy.

·  A Phase 2, prospective, interventional, open-label, multi-site extension study evaluating the long-term safety and tolerability of TAK-935 (OV935) as adjunctive therapy in patients with rare epilepsy (ENDYMION).

·  A Phase 1b/2a, placebo-controlled study investigating LP352 in subjects with developmental and epileptic encephalopathies.

·  A Phase 3, randomized, placebo-controlled trial assessing the safety and efficacy of Ganaxolone in patients with CDKL5 deficiency disorder.

• Member, Australian and New Zealand Child Neurology Society
• Active participant in epilepsy-related conferences and workshops

• AHPRA Medical Registration Number: MED0001679726